-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Benzinga·09/28/2026 15:58:45
语音播报
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.